Dishman Carbogen Amcis Ltd Q1 FY26 Earnings Analysis
Published 14 Jun 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹3.0K Cr
Price
₹185
Market Cap
₹3.0K Cr
P/E Ratio
23.1
Earnings Summary
- The company targets a low double-digit revenue growth, aiming for a CAGR of 12% to 15% over the next 3 to 5 years. - EBITDA for FY '26 is expected between INR 550 crores to INR 570 crores, targeting a 20% margin.
📊 Revenue & Sales Performance
- The company targets a low double-digit revenue growth, aiming for a CAGR of 12% to 15% over the next 3 to 5 years. (Page 10) - India CRAMS business is expected to grow by 15% to 20% in FY ‘26. (Page 9) - The Quats and Generics business is expected to grow between 5% to 10%. (Page 9) - Peak revenue from India assets could reach around INR 800 crores within 2 to 3 years. (Pages 13-14) - Bavla site's quarterly revenue is anticipated to reach around INR 100 crores in the later part of FY ‘26. (Page 15) - EBITDA targeted at INR 550 crores to INR 570 crores in FY ‘26, with potential for higher margins than 20%. (Page 22) - The company is focusing on collaboration and transferring production of molecules to India for improved utilization and margin. (Pages 13-14) - Expansion efforts include exploring new markets outside the U.S. and investing in value-added products like ADCs and conjugates. (Pages 11, 21)
📈 Profitability & Margins
- EBITDA for FY '26 is expected between INR 550 crores to INR 570 crores, targeting a 20% margin. - Revenue growth target is low double digits annually, aiming for sustained profitability alongside revenue increase. - Operating profit (EBITDA) is projected to reach around INR 750 crores within the next 2 to 3 years. - ROCE is currently low (~2%) but expected to improve to double digits (13%-15%) within 3 years due to ramp-up of various business entities. - Free cash flow generation is prioritized with a plan to reduce net debt by INR 100-200 crores annually. - Profit after tax (PAT) should improve with decreasing interest costs and amortization, though tax rate is likely to stay around 25%-30% effective. - Margins in Indian CRAMS business targeted at 20-25%, with overall company EBITDA margin aiming at 20% in FY '26. - EPS growth expected in line with EBITDA and revenue growth as profitability and efficiencies improve.
🏗️ Capital Expenditure Plans
- FY ‘26 CAPEX guidance is approximately INR 250 crores to INR 300 crores (EUR 25-30 million). - Maintenance CAPEX is around INR 170-180 crores; the remainder is growth CAPEX including digital transformation initiatives. - Large CAPEX for the French entity is mostly behind; future CAPEX will focus on expansion based on confirmed business cases. - Co-investment of EUR 25 million by a Japanese customer for a specific project; infrastructure investment is a core investment paid by the client. - Additional investments are planned in product expansion projects in Europe and India. - Focus on CAPEX only when there is committed revenue from customers to ensure returns. - Capital expenditure includes upgrades at Bavla and Naroda sites to support a peak revenue potential of INR 800 crores for India assets. - Discussions continue on alliances and strategic investments to support growth and business expansion.
💰 Fundraising & Capital Structure
- There is no explicit mention of any new fundraising through debt or equity in the provided transcript. - The company is focused on reducing net debt by INR 100 to 200 crores annually through free cash flow generation. - Most large CAPEX (e.g., French facility, digital transformation) is behind them, and future CAPEX will be based on proper business cases with customer commitments. - The management emphasizes generating free cash flow and avoiding sales that reduce profitability just to increase revenues. - Co-investment agreements with customers, such as the Japanese innovator investing EUR 25 million, are structured with customer payments funding infrastructure rather than the company raising external funds. - Debt costs are expected to decrease due to lower interest rates and goodwill amortization reduction.
📋 Order Book & Pipeline
- The transcript does not explicitly mention the current or expected order book or pending orders by a specific value. - However, the discussion indicates a positive outlook on upcoming projects, with a focus on early-phase and late-phase (Phase IIb and Phase III) projects. - The company is investing in market intelligence to identify new opportunities and potentially become a secondary supplier for risk mitigation. - There is a mention of strong interest and investment in the CRAMS business and API development with expected growth. - A co-investment of EUR 25 million with a Japanese innovator was noted, reflecting confidence from clients and a strong project pipeline. - Revenue targets imply growing order inflows to meet EBITDA of INR 550-570 crores expected for FY ‘26, and longer-term EBITDA target of INR 750 crores in 2-3 years.
Key Metrics
Frequently Asked Questions
What were Dishman Carbogen Amcis Ltd Q1 FY26 results?
- The company targets a low double-digit revenue growth, aiming for a CAGR of 12% to 15% over the next 3 to 5 years. - EBITDA for FY '26 is expected between INR 550 crores to INR 570 crores, targeting a 20% margin.
What is Dishman Carbogen Amcis Ltd share price analysis?
Dishman Carbogen Amcis Ltd currently shows a neutral. The stock trades at a P/E of 23.1 with a market cap of ₹3,046. Investors should review the full earnings analysis for detailed insights.
Is Dishman Carbogen Amcis Ltd planning capital expenditure?
- FY ‘26 CAPEX guidance is approximately INR 250 crores to INR 300 crores (EUR 25-30 million).
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
